



PUBLIKATIONSVERZEICHNIS (CHRONOLOGISCH) – CHEFARZT DR. FRANK HELDMANN,
KLINIK FÜR RHEUMATOLOGIE

1: Erler A, Fiedler J, Koch A, Schütz A, **Heldmann F**. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2-vaccine - a case report. *Arthritis Rheumatoi*. 2021 Jul 1. doi: 10.1002/art.41910. PMID: 34196469.

2: Pfeil A, Baerwald CGO, Sieburg M, Boche K, Kupka TA, Linde T, **Heldmann F**, Unger L, Oelzner P, Aringer M, Keyßer G. [Future of rheumatologists: what are the perspectives? : Survey of resident physicians in rheumatology in middle Germany]. *Z Rheumatol*. 2020 Mar;79(2):168-174. doi: 10.1007/s00393-019-00713-1. German. PubMed PMID: 31570975.

3: Keyßer G, Baerwald CGO, Sieburg M, Boche K, Pfeil A, Kupka TA, Lüthke K, **Heldmann F**, Oelzner P, Unger L, Aringer M. [Survey of rheumatologists in Saxony, Saxony-Anhalt and Thuringia regarding the occupational situation and activities in further education: no way out of the undersupply of rheumatological care]. *Z Rheumatol*. 2019 Jun;78(5):479-485. doi: 10.1007/s00393-019-0647-2. German. PubMed PMID: 31087134.

4: Webers C, Essers I, van Tubergen A, Braun J, **Heldmann F**, Baraliakos X, Boonen A. Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach. *Arthritis Care Res (Hoboken)*. 2018 Apr;70(4):608-616. doi: 10.1002/acr.23299. Epub 2018 Feb 18. PubMed PMID: 28575536; PubMed Central PMCID: PMC5901401.

5: Kiltz U, von Zabern C, Baraliakos X, **Heldmann F**, Mintrop B, Sarholz M, Krause D, Dybowski F, Kalthoff L, Braun J. Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study. *Arthritis Res Ther*. 2017 Apr 7;19(1):73. doi: 10.1186/s13075-017-1279-z. PubMed PMID: 28388956; PubMed Central PMCID: PMC5383975.

6: Baraliakos X, **Heldmann F**, Callhoff J, Suppiah R, McQueen FM, Krause D, Klink C, Schmitz-Bortz E, Igelmann M, Kalthoff L, Kiltz U, Schmuelderich A, Braun J. Quantification of Bone Marrow Edema by Magnetic Resonance Imaging Only Marginally Reflects Clinical Neck Pain Evaluation in Rheumatoid Arthritis and Ankylosing Spondylitis. *J Rheumatol*. 2016 Dec;43(12):2131-2135. Epub 2016 Oct 15. PubMed PMID: 27744396.

7: Baraliakos X, **Heldmann F**, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J. Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. *RMD Open*. 2016 Jul 19;2(2):e000272. doi: 10.1136/rmdopen-2016-000272. eCollection 2016. PubMed PMID: 27493791; PubMed Central PMCID: PMC4964174.

8: **Heldmann F**, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and



safety. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90. Epub 2016 Mar 25. PubMed PMID: 27049733.

9: Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, **Heldmann F**, Kiltz U, Köhm M, König R, Leipe J, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H. [Do we still need clinical studies in rheumatology?]. Z Rheumatol. 2016 Feb;75(1):4-10. doi: 10.1007/s00393-015-1687-x. German. PubMed PMID: 26680367.

10: Essers I, van Tubergen A, **Heldmann F**, Baraliakos X, Braun J, Kiltz U, Boonen A. Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors. RMD Open. 2015 Nov 17;1(1):e000164. doi: 10.1136/rmdopen-2015-000164. eCollection 2015. PubMed PMID: 26629367; PubMed Central PMCID: PMC4654100.

11: Tran-Duy A, Nguyen TT, Thijs H, Baraliakos X, **Heldmann F**, Braun J, Boonen A. Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis. Arthritis Care Res (Hoboken). 2015 Nov;67(11):1578-85. doi: 10.1002/acr.22655. PubMed PMID: 26216525.

12: Braun J, Kiltz U, Sarholz M, **Heldmann F**, Regel A, Baraliakos X. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015;11(8):935-46. doi: 10.1586/1744666X.2015.1052795. Epub 2015 Jun 5. Review. PubMed PMID: 26048334.

13: Braun J, Kiltz U, **Heldmann F**, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015 Mar;20(1):1-14. doi: 10.1517/14728214.2015.993378. Epub 2015 Jan 9. Review. PubMed PMID: 25575936.

14: Braun J, Baraliakos X, Kiltz U, **Heldmann F**, Sieper J. Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference? J Rheumatol. 2015 Jan;42(1):31-8. doi: 10.3899/jrheum.130959. Epub 2014 Nov 15. Review. PubMed PMID: 25399389.

15: **Heldmann F**, Kiltz U, Baraliakos X, Braun J. [SAPHO syndrome]. Z Rheumatol. 2014 Oct;73(8):729-41. doi: 10.1007/s00393-014-1460-6. German. PubMed PMID: 25260820.

16: Braun J, Baraliakos X, **Heldmann F**, Kiltz U. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Investig Drugs. 2014 May;23(5):647-59. doi: 10.1517/13543784.2014.899351. Epub 2014 Mar 22. Review. PubMed PMID: 24654630.

17: Braun J, Baraliakos X, **Heldmann F**, Kiltz U. [What is ascertained in the therapy of axial spondyloarthritis?]. Internist (Berl). 2013 Dec;54(12):1450-8. doi: 10.1007/s00108-013-3331-7. Review. German. Erratum in: Internist (Berl). 2014 Jan;55(1):106. Baraliakos, X [added]; Heldmann, F [added]; Kiltz, U [added]. PubMed PMID: 24281787.



18: Baraliakos X, Kiltz U, **Heldmann F**, Sieper J, Braun J. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. *Clin Exp Rheumatol.* 2013 Jul-Aug;31(4 Suppl 78):S43-6. Epub 2013 Oct 3. Review. PubMed PMID: 24129136.

19: Baraliakos X, **Heldmann F**, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. *Ann Rheum Dis.* 2014 Oct;73(10):1819-25. doi: 10.1136/annrheumdis-2013-203425. Epub 2013 Jul 14. PubMed PMID: 23852807.

20: Baraliakos X, Haibel H, Fritz C, Listing J, **Heldmann F**, Braun J, Sieper J. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. *Arthritis Res Ther.* 2013;15(3):R67. PubMed PMID: 23786760; PubMed Central PMCID: PMC4060369.

21: Haibel H, **Heldmann F**, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. *Arthritis Rheum.* 2013 Aug;65(8):2211-3. doi: 10.1002/art.38014. PubMed PMID: 23686466.

22: Baraliakos X, Baerlecken N, Witte T, **Heldmann F**, Braun J. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. *Ann Rheum Dis.* 2014 Jun;73(6):1079-82. doi: 10.1136/annrheumdis-2012-202177. Epub 2013 May 3. PubMed PMID: 23644552.

23: Song IH, **Heldmann F**, Rudwaleit M, Listing J, Appel H, Haug-Rost I, Braun J, Sieper J. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. *Ann Rheum Dis.* 2013 Feb;72(2):305-6. doi: 10.1136/annrheumdis-2012-201926. Epub 2012 Aug 11. PubMed PMID: 22887847.

24: Kiltz U, **Heldmann F**, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? *Curr Opin Rheumatol.* 2012 May;24(3):252-60. doi: 10.1097/BOR.0b013e3283524b82. Review. PubMed PMID: 22450391.

25: Fendler C, Saracbası E, Dybowski F, **Heldmann F**, Braun J. [Practical problems by implementation of vaccination recommendations]. *Z Rheumatol.* 2012 Feb;71(2):147-50, 153-5. doi: 10.1007/s00393-011-0946-8. German. PubMed PMID: 22370806.

26: Dybowski F, Moos F, Saracbası-Zender E, **Heldmann F**, Braun J. [Generalized osteoarthritis in a young adult with type II collagenopathy]. *Dtsch Med Wochenschr.* 2011 Oct;136(42):2147-51. doi: 10.1055/s-0031-1292026. Epub 2011 Oct 11. German. PubMed PMID: 21990059.



27: **Heldmann F**, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. *Clin Exp Rheumatol*. 2011 Jul-Aug;29(4):672-80. Epub 2011 Aug 31. PubMed PMID: 21906431.

28: Song IH, **Heldmann F**, Rudwaleit M, Haibel H, Weiss A, Braun J, Sieper J. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. *Ann Rheum Dis*. 2011 Jun;70(6):1108-10. doi: 10.1136/ard.2010.145946. Epub 2011 Mar 17. PubMed PMID: 21415053.

29: **Heldmann F**, Dybowski F, Baraliakos X, Braun J. [Perioperative use of biologicals in rheumatoid arthritis]. *Z Rheumatol*. 2011 Jan;70(1):14-20. doi: 10.1007/s00393-010-0680-7. German. PubMed PMID: 21267736.

30: **Heldmann F**, Braun J. Perioperative use of methotrexate. *Clin Exp Rheumatol*. 2010 Sep-Oct;28(5 Suppl 61):S110-3. Epub 2010 Oct 28. Review. PubMed PMID: 21044442.

31: **Heldmann F**, Dybowski F, Saracbası-Zender E, Fendler C, Braun J. Update on biologic therapy in the management of axial spondyloarthritis. *Curr Rheumatol Rep*. 2010 Oct;12(5):325-31. doi: 10.1007/s11926-010-0125-y. PubMed PMID: 20665135.

32: Song IH, **Heldmann F**, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. *Arthritis Rheum*. 2010 May;62(5):1290-7. doi: 10.1002/art.27383. PubMed PMID: 20461780.

33: Haibel H, Rudwaleit M, Listing J, **Heldmann F**, Wong RL, Kupper H, Braun J, Sieper J. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis Rheum*. 2008 Jul;58(7):1981-91. doi: 10.1002/art.23606. PubMed PMID: 18576337.

34: **Heldmann F**, Brandt J, Schoppe H, Braun J. [A 46-year-old-patient with granulomatous prostatitis, arthralgia and haemorrhagic rhinitis]. *Dtsch Med Wochenschr*. 2006 Jan 5;131(1-2):22-5. German. PubMed PMID: 16374738.